top of page

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Jun 12, 2023

Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.

Recent Posts

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

Cambridge, UK based Amphista Therapeutics is developing a new generation of targeted protein degradation therapies that do not rely on cereblon or VHL

Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them

Cambridge, UK based Ignota Labs raised a $6.9M seed funding today and will use AI to understand why otherwise promising therapies have failed on tox by surprise and then to reengineer them

With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline

With unique license agreements in place with local universities and an additional $260M recently raised, Cambridge, UK based Apollo Therapeutics is building out a substantial pipeline

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page